Redeye has made only minor revisions to its forecast following Modelon’s Q2 report, in which the rep...
26% organic sales growth y-o-y Growth initiatives hurt profitability mid-term Pricing to act as a ta...
2024e-'26e EBIT raised by 5% We are above the upper end of guidance Strong order book and robust out...
Updating estimates after full release of H1 numbers More guidance upgrades possible + M&A increasing...
ExpreS2ion Biotech har tagit ett steg närmare att inleda en first-in-human studie med sitt bröstcanc...
Redeye comments on Nekkar’s H1’24 report that posted mixed results, with continued revenue growth in...
Interimsdata ger ytterligare stöd Interimsdata som presenterades sent under kvartalet från bolagets ...
Net sales were 9% lower than our estimate. Costs were in line with our expectations, which led to lo...
Idag publicerade Fable Media sin delårsrapport för kv2 2024.
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
Q2 revenue 29% below, won't meet '24 guidance Design win with SigmaX.
PMDS is on track to reach positive cash flow by the year-end 2024, and the company will repeat its t...
Redeye provides its initial take on Navigo’s Q2 2024 report, which came in just slightly below our e...
Redeye comments on Northbaze Q2 2024 report. The Q2 2024 report was better than expected with sales ...
Redeye raises its base case following the positive readout in the phase IIa RVO study with ANXV.
Redeye views Acarix's Q2 as weaker than anticipated, with lower-than-expected revenues.
STENOCARE published on August 21st the company’s Q2-report for 2024.
Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequ...
Redeye comments on Better Collective’s Q2-results which were in line with expectations, albeit with ...
Redeye sees a mixed Q2 report from BrightBid, with slow q/q cARR growth as the weak spot and solid c...
